WO2009019612A3 - Lentiviral gene transfer vectors and their medicinal applications - Google Patents
Lentiviral gene transfer vectors and their medicinal applications Download PDFInfo
- Publication number
- WO2009019612A3 WO2009019612A3 PCT/IB2008/002930 IB2008002930W WO2009019612A3 WO 2009019612 A3 WO2009019612 A3 WO 2009019612A3 IB 2008002930 W IB2008002930 W IB 2008002930W WO 2009019612 A3 WO2009019612 A3 WO 2009019612A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene transfer
- transfer vectors
- vectors
- treatment
- administration
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 7
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 206010061598 Immunodeficiency Diseases 0.000 abstract 2
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000007813 immunodeficiency Effects 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 238000002255 vaccination Methods 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 238000009109 curative therapy Methods 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 238000002636 symptomatic treatment Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008285224A AU2008285224B2 (en) | 2007-08-03 | 2008-08-01 | Lentiviral gene transfer vectors and their medicinal applications |
DK08827144.0T DK2185192T3 (en) | 2007-08-03 | 2008-08-01 | LENTIVIRAL TRANSFER VECTORS AND THEIR MEDICAL USES |
JP2010519544A JP5773648B2 (en) | 2007-08-03 | 2008-08-01 | Lentiviral gene transfer vectors and their application to pharmaceuticals |
EP08827144.0A EP2185192B1 (en) | 2007-08-03 | 2008-08-01 | Lentiviral gene transfer vectors and their medicinal applications |
US12/671,898 US8420104B2 (en) | 2007-08-03 | 2008-08-01 | Lentiviral gene transfer vectors and their medicinal applications |
MX2014010835A MX342449B (en) | 2007-08-03 | 2008-08-01 | Lentiviral gene transfer vectors and their medicinal applications. |
CA2695433A CA2695433A1 (en) | 2007-08-03 | 2008-08-01 | Lentiviral gene transfer vectors and their medicinal applications |
MX2010001379A MX2010001379A (en) | 2007-08-03 | 2008-08-01 | Lentiviral gene transfer vectors and their medicinal applications. |
ES08827144T ES2708856T3 (en) | 2007-08-03 | 2008-08-01 | Vectors of lentiviral gene transfer and its medicinal applications |
CN200880110278.7A CN102083462B (en) | 2007-08-03 | 2008-08-01 | Lentiviral gene transfer vectors and their medicinal applications |
BRPI0813194A BRPI0813194B8 (en) | 2007-08-03 | 2008-08-01 | kit, lentiviral vector particles, composition of plasmid vectors, chimeric hiv-1 derived antigen, vsv-g envelope protein, nucleic acid molecules, immunogenic composition and use of a lentiviral vector |
US13/453,784 US8709799B2 (en) | 2007-08-03 | 2012-04-23 | Lentiviral gene transfer vectors and their medicinal applications |
US14/197,532 US9328146B2 (en) | 2007-08-03 | 2014-03-05 | Lentiviral gene transfer vectors and their medicinal applications |
IL243569A IL243569A (en) | 2007-08-03 | 2016-01-11 | Lentiviral gene transfer vectors and their medicinal applications |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07290980.7 | 2007-08-03 | ||
EP07290979.9 | 2007-08-03 | ||
EP07290980.7A EP2020444B1 (en) | 2007-08-03 | 2007-08-03 | Defective non-integrative lentiviral transfer vectors for vaccines |
EP07290979 | 2007-08-03 | ||
EP07291251.2A EP2047861B1 (en) | 2007-10-12 | 2007-10-12 | Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications |
EP07291251.2 | 2007-10-12 | ||
EP08156405.6 | 2008-05-16 | ||
EP08156405 | 2008-05-16 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/671,898 A-371-Of-International US8420104B2 (en) | 2007-08-03 | 2008-08-01 | Lentiviral gene transfer vectors and their medicinal applications |
US13/453,784 Continuation US8709799B2 (en) | 2007-08-03 | 2012-04-23 | Lentiviral gene transfer vectors and their medicinal applications |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009019612A2 WO2009019612A2 (en) | 2009-02-12 |
WO2009019612A3 true WO2009019612A3 (en) | 2009-12-23 |
Family
ID=40341833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2008/002930 WO2009019612A2 (en) | 2007-08-03 | 2008-08-01 | Lentiviral gene transfer vectors and their medicinal applications |
Country Status (14)
Country | Link |
---|---|
US (3) | US8420104B2 (en) |
EP (1) | EP2185192B1 (en) |
JP (3) | JP5773648B2 (en) |
CN (2) | CN102083462B (en) |
AU (1) | AU2008285224B2 (en) |
BR (1) | BRPI0813194B8 (en) |
CA (1) | CA2695433A1 (en) |
DK (1) | DK2185192T3 (en) |
ES (1) | ES2708856T3 (en) |
HK (1) | HK1252608A1 (en) |
IL (1) | IL243569A (en) |
MX (2) | MX342449B (en) |
PT (1) | PT2185192T (en) |
WO (1) | WO2009019612A2 (en) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0701253D0 (en) | 2007-01-23 | 2007-02-28 | Diagnostics For The Real World | Nucleic acid amplification and testing |
PT2185192T (en) | 2007-08-03 | 2019-02-12 | Pasteur Institut | Lentiviral gene transfer vectors and their medicinal applications |
WO2010129602A2 (en) * | 2009-05-04 | 2010-11-11 | Fred Hutchinson Cancer Research Center | Cocal vesiculovirus envelope pseudotyped retroviral vectors |
EP2366776A1 (en) * | 2010-03-01 | 2011-09-21 | Epixis | A method for measuring viral infectivity |
EP2385107B1 (en) | 2010-05-03 | 2016-08-24 | Institut Pasteur | Lentiviral vector based immunological compounds against malaria |
EP2666477A1 (en) | 2012-05-23 | 2013-11-27 | Theravectys | Lentiviral vectors containing an MHC class I promoter |
WO2011147622A1 (en) | 2010-05-26 | 2011-12-01 | Deutsches Rheuma-Forschungszentrum Berlin | Antigen-presenting modified naïve b cells for immune suppression and a method for producing said modified cells |
CN102277380B (en) * | 2010-06-08 | 2013-03-27 | 齐鲁制药有限公司 | A dhfr complementarily expressed cotransfection eukaryotic expression vector and preparation method and application thereof |
TW201217186A (en) | 2010-06-25 | 2012-05-01 | Omarco Network Solutions Ltd | Security improvements for flexible substrates |
EP2643343A1 (en) | 2010-11-26 | 2013-10-02 | Institut Pasteur | Identification of a human gyrovirus and applications. |
JP6054942B2 (en) | 2011-04-08 | 2016-12-27 | イミューン デザイン コーポレイション | Immunogenic compositions and methods of using the compositions to elicit humoral and cellular immune responses |
WO2013083753A2 (en) | 2011-12-07 | 2013-06-13 | Institut Pasteur | Identification of a swine parecho-like virus and applications |
GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
WO2013140169A1 (en) * | 2012-03-20 | 2013-09-26 | Isis Innovation Limited | Immunogenic composition and methods of use thereof |
US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
KR102070472B1 (en) | 2012-03-30 | 2020-01-29 | 이뮨 디자인 코포레이션 | Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign |
US20150182617A1 (en) | 2012-07-25 | 2015-07-02 | Theravectys | Glycoproteins for pseudotyping lentivectors |
FR2996856B1 (en) * | 2012-10-15 | 2015-06-05 | Agronomique Inst Nat Rech | RECOMBINANT NOVIRHABDOVIRUS USEFUL AS ANTIGEN VECTOR |
AU2013358922B2 (en) | 2012-12-14 | 2019-08-22 | The Regents Of The University Of California | Viral vector nanocapsule for targeting gene therapy and its preparation |
BR112015030211A2 (en) | 2013-06-03 | 2017-08-22 | Theravectys | LENTIVIRAL VECTORS CONTAINING A CLASS I MHC, CLASS II MHC, OR BETA-2 MICROGLOBULIN BETWEEN PROMOTER SEQUENCE |
EP3009144A1 (en) * | 2014-10-15 | 2016-04-20 | Theravectys | Lentiviral vectors for inducing CD4+ and CD8+ immune responses in vaccination of humans |
WO2015063707A1 (en) * | 2013-10-31 | 2015-05-07 | Theravectys | LENTIVIRAL VECTORS FOR INDUCING CD4+ and CD8+ IMMUNE RESPONSES IN VACCINATION OF HUMANS |
EP2878674A1 (en) * | 2013-11-28 | 2015-06-03 | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) | Stable episomes based on non-integrative lentiviral vectors |
EP2878667A1 (en) | 2013-11-29 | 2015-06-03 | Institut Pasteur | TAL effector means useful for partial or full deletion of DNA tandem repeats |
AU2015208731A1 (en) * | 2014-01-27 | 2016-08-04 | Theravectys | Lentiviral vectors for generating immune responses against Human T Lymphotrophic Virus Type 1 |
KR102416194B1 (en) * | 2014-03-01 | 2022-07-04 | 프로펙츄스 바이오사이언스, 인크. | Recombinant isfahan viral vectors |
IL292577A (en) | 2014-09-07 | 2022-06-01 | Selecta Biosciences Inc | Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses |
EP3031923A1 (en) | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
EP3211003A1 (en) | 2016-02-24 | 2017-08-30 | Institut Pasteur | T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
US11185555B2 (en) | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
EP3235828A1 (en) * | 2016-04-21 | 2017-10-25 | Genethon | Stable pseudotyped lentiviral particles and uses thereof |
EP3455239B1 (en) * | 2016-05-13 | 2021-04-07 | Flash Therapeutics | Particle for the encapsidation of a genome engineering system |
CN106399376A (en) * | 2016-08-31 | 2017-02-15 | 河南省华隆生物技术有限公司 | Integration-defective lentiviral vector as well as preparation method and application thereof |
AU2018205496A1 (en) | 2017-01-07 | 2019-07-25 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
JP2020506695A (en) | 2017-01-30 | 2020-03-05 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Recombinant viral vector for treating glycogen disease |
MX2019011599A (en) | 2017-03-30 | 2019-12-19 | Univ Queensland | "chimeric molecules and uses thereof". |
FR3065967B1 (en) * | 2017-05-05 | 2022-06-03 | Univ Paris Descartes | IN VITRO METHOD FOR DETECTION AND QUANTIFICATION OF HIV-2 DNA |
US20200216502A1 (en) * | 2017-09-22 | 2020-07-09 | Centre National De La Recherche Scientifique (Cnrs) | Mutated Glycoprotein of Vesicular Stomatitis Virus |
EP3689337A4 (en) * | 2017-09-28 | 2021-12-15 | Tandem Co., Ltd. | Novel recombinant plasma membrane-based vesicle, for treating cancer |
JP6994714B2 (en) | 2017-10-03 | 2022-01-14 | 東亞合成株式会社 | Antiviral peptides and their uses |
BR112020007157A2 (en) | 2017-10-13 | 2020-09-24 | Selecta Biosciences, Inc. | methods and compositions for the attenuation of viral transfer anti-vector igm responses |
CN111225682A (en) * | 2017-10-20 | 2020-06-02 | 吉尼松公司 | Use of syncytin for targeted delivery of drugs and genes to lung tissue |
AU2018365296B2 (en) | 2017-11-09 | 2023-11-23 | Institut Pasteur | A Zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition |
CA3092372A1 (en) | 2018-02-26 | 2019-08-29 | AnTolRx, Inc. | Tolerogenic liposomes and methods of use thereof |
JP6917942B2 (en) | 2018-04-11 | 2021-08-11 | 株式会社日立製作所 | Data analysis server, data analysis system, and data analysis method |
CN110577585A (en) * | 2018-06-07 | 2019-12-17 | 中国医学科学院基础医学研究所 | Vesicular stomatitis virus envelope glycoprotein variant, and construction method and application thereof |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
CN113631703A (en) * | 2018-12-04 | 2021-11-09 | 西瑞恩生物科技股份有限公司 | Viral transduction using poloxamine |
KR20210149251A (en) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | Human carbonic anhydrase 2 compositions and methods for tunable modulation |
BR112021021566A2 (en) | 2019-04-28 | 2022-04-19 | Selecta Biosciences Inc | Methods for treating individuals with preexisting immunity to viral transfer vectors |
EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
CN114206396A (en) | 2019-05-28 | 2022-03-18 | 西莱克塔生物科技公司 | Methods and compositions for attenuating an immune response against an antiviral transfer vector |
EP3770264A1 (en) | 2019-07-22 | 2021-01-27 | Genethon | Precise integration using nuclease targeted idlv |
US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
IL296319A (en) * | 2020-03-09 | 2022-11-01 | Janssen Biotech Inc | Compositions and methods for quantifying integration of recombinant vector nucleic acid |
CN111593073B (en) * | 2020-03-18 | 2022-03-08 | 睿丰康生物医药科技(浙江)有限公司 | Double-reporter gene framework vector, four-plasmid pseudovirus packaging system and new packaging corolla pneumonia pseudovirus |
US20230365989A1 (en) * | 2020-03-20 | 2023-11-16 | The Broad Institute, Inc. | Compositions and methods for enhanced lentiviral production |
JP2023539761A (en) * | 2020-09-01 | 2023-09-19 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Improving the generation of lentiviral vectors for T cell transduction using cocal envelopes |
KR102379144B1 (en) * | 2020-09-29 | 2022-03-28 | 한국표준과학연구원 | SARS-CoV-2 RNA Reference material and Method for providing the information for diagnosis of infection of SARS-CoV-2 using the same |
KR102283733B1 (en) * | 2020-12-22 | 2021-08-02 | 한국표준과학연구원 | SARS-CoV-2 packaged RNA reference material for COVID-19 virus diagnosis, preparation method and use thereof |
CN114107393A (en) | 2021-04-07 | 2022-03-01 | 上海劲威生物科技有限公司 | Lentiviral vector and lentiviral particle for treating hepatitis B as well as preparation methods and applications of lentiviral vector and lentiviral particle |
CN115247190A (en) * | 2021-04-28 | 2022-10-28 | 沛尔生技医药股份有限公司 | Lentiviral packaging system, lentivirus prepared by same, cell transduced by same and application thereof |
CA3217862A1 (en) | 2021-05-05 | 2022-11-10 | Radius Pharmaceuticals, Inc. | Animal model having homologous recombination of mouse pth1 receptor |
AU2022301302A1 (en) | 2021-07-01 | 2024-01-25 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
CA3227108A1 (en) | 2021-08-11 | 2023-02-16 | Xiaomeng HU | Genetically modified primary cells for allogeneic cell therapy |
AU2022325231A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
AU2022326565A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
WO2023019225A2 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
WO2023084094A1 (en) * | 2021-11-15 | 2023-05-19 | Theravectys | Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers |
CN114181972A (en) * | 2021-11-23 | 2022-03-15 | 上海本导基因技术有限公司 | Lentiviral vectors suitable for gene therapy of refractory angiogenic eye diseases |
WO2023114918A1 (en) | 2021-12-16 | 2023-06-22 | Ludwig Institute For Cancer Research Ltd | Antisense transfer vectors and methods of use thereof |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
WO2023173123A1 (en) | 2022-03-11 | 2023-09-14 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
WO2024023135A1 (en) * | 2022-07-27 | 2024-02-01 | Theravectys | Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004110485A1 (en) * | 2003-06-13 | 2004-12-23 | Palmowski Michael J | Materials and methods for improved vaccination |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2337429T3 (en) * | 1999-10-11 | 2010-04-23 | Institut Pasteur | LENTIVIRAL VECTORS FOR THE PREPARATION OF IMMUNOTHERAPEUTIC COMPOSITIONS. |
AU2001262684A1 (en) * | 2000-06-01 | 2001-12-11 | Dnavec Research Inc. | Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity |
CA2422882A1 (en) | 2000-09-15 | 2002-03-21 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
US7575924B2 (en) * | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
WO2002090558A1 (en) | 2001-05-03 | 2002-11-14 | Fit Biotech Oyj Plc | Novel expression vectors and uses thereof |
CA2449589A1 (en) | 2001-06-08 | 2002-12-19 | Dnavec Research Inc. | Gene transfer into primate embryonic stem cells using vsv-g pseudotyped simian immunodeficiency virus vector |
AU2002363189A1 (en) | 2001-10-31 | 2003-05-12 | The South African Medical Research Council | Hiv-1 subtype isolate regulatory/accessory genes, and modifications and derivatives thereof |
WO2005028634A2 (en) | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
FR2872170B1 (en) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | NON-INTERACTIVE AND NON-REPLICATIVE LENTIVIRUS, PREPARATION AND USES |
KR101253363B1 (en) * | 2004-10-13 | 2013-04-15 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | Improved adenoviral vectors and uses thereof |
AU2006251621A1 (en) * | 2005-05-20 | 2006-11-30 | Virxsys Corporation | Transduction of primary cells |
WO2006130855A2 (en) * | 2005-06-01 | 2006-12-07 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
ES2281252B1 (en) | 2005-07-27 | 2009-02-16 | Consejo Superior De Investigaciones Cientificas | RECOMBINANT VECTORS BASED ON THE MODIFIED ANKARA VIRUS (MVA) AS PREVENTIVE AND THERAPEUTIC VACCINES AGAINST AIDS. |
WO2007054792A1 (en) | 2005-11-08 | 2007-05-18 | South African Medical Research Council | Chimaeric hiv-1 subtype c gag-virus-like particles |
US20090104153A1 (en) | 2005-12-21 | 2009-04-23 | Barber Karen A | Method of eliciting immune response |
GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
WO2007091066A1 (en) | 2006-02-07 | 2007-08-16 | Ucl Business Plc | Applications of non-integrating lentiviral vectors |
PT2185192T (en) * | 2007-08-03 | 2019-02-12 | Pasteur Institut | Lentiviral gene transfer vectors and their medicinal applications |
-
2008
- 2008-08-01 PT PT08827144T patent/PT2185192T/en unknown
- 2008-08-01 MX MX2014010835A patent/MX342449B/en unknown
- 2008-08-01 ES ES08827144T patent/ES2708856T3/en active Active
- 2008-08-01 AU AU2008285224A patent/AU2008285224B2/en active Active
- 2008-08-01 WO PCT/IB2008/002930 patent/WO2009019612A2/en active Application Filing
- 2008-08-01 MX MX2010001379A patent/MX2010001379A/en active IP Right Grant
- 2008-08-01 DK DK08827144.0T patent/DK2185192T3/en active
- 2008-08-01 CN CN200880110278.7A patent/CN102083462B/en active Active
- 2008-08-01 EP EP08827144.0A patent/EP2185192B1/en active Active
- 2008-08-01 JP JP2010519544A patent/JP5773648B2/en active Active
- 2008-08-01 CN CN201511036366.5A patent/CN108114276A/en active Pending
- 2008-08-01 BR BRPI0813194A patent/BRPI0813194B8/en active IP Right Grant
- 2008-08-01 CA CA2695433A patent/CA2695433A1/en active Pending
- 2008-08-01 US US12/671,898 patent/US8420104B2/en active Active
-
2012
- 2012-04-23 US US13/453,784 patent/US8709799B2/en active Active
-
2014
- 2014-03-05 US US14/197,532 patent/US9328146B2/en active Active
- 2014-11-21 JP JP2014237117A patent/JP2015062425A/en active Pending
-
2016
- 2016-01-11 IL IL243569A patent/IL243569A/en active IP Right Grant
-
2018
- 2018-01-05 JP JP2018000479A patent/JP6480028B2/en active Active
- 2018-09-17 HK HK18111908.8A patent/HK1252608A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004110485A1 (en) * | 2003-06-13 | 2004-12-23 | Palmowski Michael J | Materials and methods for improved vaccination |
Non-Patent Citations (11)
Title |
---|
BALIGA ET AL: "Vaccination of Mice with Replication-Defective Human Immunodeficiency Virus Induces Cellular and Humoral Immunity and Protects against Vaccinia Virus-gag Challenge", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 14, no. 3, 12 August 2006 (2006-08-12), pages 432 - 441, XP005844837, ISSN: 1525-0016 * |
BUFFA VIVIANA ET AL: "A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice", JOURNAL OF GENERAL VIROLOGY, vol. 87, no. Part 6, June 2006 (2006-06-01), pages 1625 - 1634, XP002552701, ISSN: 0022-1317 * |
BUFFA VIVIANA ET AL: "Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo.", VIRAL IMMUNOLOGY WINTER 2006, vol. 19, no. 4, January 2006 (2006-01-01), pages 690 - 701, XP002482736, ISSN: 0882-8245 * |
DELENDA C: "LENTIVIRAL VECTORS: OPTIMIZATION OF PACKAGING, TRANSDUCTION AND GENE EXPRESSION", JOURNAL OF GENE MEDICINE, WILEY,, US, vol. 6, no. SUPPL 1, February 2004 (2004-02-01), pages S125 - S138, XP008051607, ISSN: 1099-498X * |
FENG GAO ET AL: "CODON USAGE OPTIMIZATION OF HIV TYPE 1 SUBTYPE C GAG, POL, ENV, AND NEF GENES: IN VITRO EXPRESSION AND IMMUNE RESPONSES IN DNA-VACCINATED MICE", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, vol. 19, no. 9, 1 January 2003 (2003-01-01), pages 817 - 823, XP009025628, ISSN: 0889-2229 * |
GOMEZ ET AL: "Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1IIIB Gag-Pol-Nef proteins of clade B", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 25, no. 15, 16 March 2007 (2007-03-16), pages 2863 - 2885, XP005939185, ISSN: 0264-410X * |
IGLESIAS MARIA CANDELA ET AL: "Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses invivo", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 15, no. 6, 1 June 2007 (2007-06-01), pages 1203 - 1210, XP008087284, ISSN: 1525-0016 * |
KEIL W ET AL: "EPITOPE MAPPING BY DELETION MUTANTS AND CHIMERAS OF TWO VESICULAR STOMATITIS VIRUS GLYCOPROTEIN GENES EXPRESSED BY A VACCINIA VIRUS VECTOR", VIROLOGY, vol. 170, no. 2, 1989, pages 392 - 407, XP002473034, ISSN: 0042-6822 * |
NEGRI DONATELLA RM ET AL: "Successful immunization with a single injection of non-integrating lentiviral vector", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 15, no. 9, 26 June 2007 (2007-06-26), pages 1716 - 1723, XP008087256, ISSN: 1525-0016 * |
PICHLMAIR ANDREAS ET AL: "Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via toll-like receptor 9", JOURNAL OF VIROLOGY, vol. 81, no. 2, January 2007 (2007-01-01), pages 539 - 547, XP002473033, ISSN: 0022-538X * |
ROLLMAN ET AL: "The rationale behind a vaccine based on multiple HIV antigens", MICROBES AND INFECTION, ELSEVIER, PARIS, FR, vol. 7, no. 14, November 2005 (2005-11-01), pages 1414 - 1423, XP005171715, ISSN: 1286-4579 * |
Also Published As
Publication number | Publication date |
---|---|
HK1252608A1 (en) | 2019-05-31 |
US8709799B2 (en) | 2014-04-29 |
WO2009019612A2 (en) | 2009-02-12 |
BRPI0813194B8 (en) | 2021-05-25 |
JP6480028B2 (en) | 2019-03-06 |
EP2185192A2 (en) | 2010-05-19 |
US20100297168A1 (en) | 2010-11-25 |
AU2008285224A1 (en) | 2009-02-12 |
JP2015062425A (en) | 2015-04-09 |
BRPI0813194B1 (en) | 2020-05-05 |
CN102083462A (en) | 2011-06-01 |
JP2018076363A (en) | 2018-05-17 |
JP5773648B2 (en) | 2015-09-02 |
EP2185192B1 (en) | 2018-10-31 |
CN102083462B (en) | 2015-02-18 |
JP2010535495A (en) | 2010-11-25 |
US9328146B2 (en) | 2016-05-03 |
MX342449B (en) | 2016-09-29 |
AU2008285224B2 (en) | 2015-01-22 |
IL243569A (en) | 2016-07-31 |
BRPI0813194A2 (en) | 2016-11-01 |
ES2708856T3 (en) | 2019-04-11 |
US20120315296A1 (en) | 2012-12-13 |
PT2185192T (en) | 2019-02-12 |
US8420104B2 (en) | 2013-04-16 |
MX2010001379A (en) | 2010-06-08 |
US20140248306A1 (en) | 2014-09-04 |
CN108114276A (en) | 2018-06-05 |
CA2695433A1 (en) | 2009-02-12 |
DK2185192T3 (en) | 2019-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009019612A3 (en) | Lentiviral gene transfer vectors and their medicinal applications | |
Huang et al. | OmpW is a potential target for eliciting protective immunity against Acinetobacter baumannii infections | |
Sharma et al. | Protective efficacy of piperine against Mycobacterium tuberculosis | |
WO2010036938A3 (en) | Nanoemulsion therapeutic compositions and methods of using the same | |
Wahida et al. | Rethinking phage-bacteria-eukaryotic relationships and their influence on human health | |
Qadir | Phage Therapy: a modern tool to control bacterial infections. | |
WO2009051837A3 (en) | Vaccine nanotechnology | |
BR112013012555A2 (en) | Immunogenic peptides for use in the prevention and / or treatment of infectious diseases, autoimmune diseases, immune responses to allopaths, allergic diseases, tumors, graft rejection, and immune responses against viral vectors used for gene therapy or gene vaccination. | |
Huang et al. | Grouper (Epinephelus coioides) antimicrobial peptide epinecidin-1 exhibits antiviral activity against foot-and-mouth disease virus in vitro | |
MX351380B (en) | Bovine viral diarrhea virus type 1b vaccine compositions and methods. | |
WO2005028496A3 (en) | Vaccine for treatment and prevention of herpes simplex virus infection | |
Giri et al. | Effects of intracellular products of Bacillus subtilis VSG1 and Lactobacillus plantarum VSG3 on cytokine responses in the head kidney macrophages of Labeo rohita | |
Klem et al. | Bacteriophage therapy against staphylococci | |
Roy et al. | Insect natural products as potential source for alternative medicines-a review | |
Sankar et al. | Nosodes and sarcodes | |
JP2017529398A5 (en) | ||
Sarker | Induction of Humoral Immunity Through the Enhancement of IgM Production in Murine Splenic Cells by Ethanolic Extract of Seed of Piper nigrum L. | |
Fuerte-Stone et al. | Host happy hour: Phage cocktail targets IBD-associated microbes | |
IL208862A (en) | Use of a protein capable of stimulating an immune response against a tat protein in the preparation of a medicament for preventing or treating acquired immunodeficiency syndrome (aids) in a patient and a composition and vaccine related thereto | |
Riedmann | Two therapeutic HPV vaccine candidates successful in phase 1. | |
Shi et al. | The antitumor effects of Newcastle disease virus on glioma | |
Tran et al. | Common dandelion (Taraxacum officinale) leaf extract efficiently inhibits SARS-CoV-2 Omicron infection in vitro | |
Zou et al. | Improving the safety and efficacy of phage therapy from the perspective of phage-mammal interactions | |
Sun et al. | From trash to treasure: the role of bacterial extracellular vesicles in gut health and disease | |
WO2000077177A3 (en) | Isolation of a human retrovirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880110278.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08827144 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008285224 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2695433 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 203694 Country of ref document: IL Ref document number: 2010519544 Country of ref document: JP Ref document number: MX/A/2010/001379 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008827144 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008285224 Country of ref document: AU Date of ref document: 20080801 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1196/DELNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12671898 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 243569 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: PI0813194 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100203 |